Japanese drug companies Daiichi Sankyo (TYO: 4568) and UMN Pharma (TSE: 4585) have signed a collaborative research agreement for norovirus vaccine.
In the Immunization and Vaccine Committee the Health Science Council of Japan’s Ministry of Health, Labor and Welfare, held in December 2013, norovirus vaccine was selected as one of the vaccines with a high development priority.
Under the terms of the agreement, UMN Pharma will provide Daiichi Sankyo with recombinant norovirus virus-like particle (VLP) antigen which has been produced by a cell-culture manufacturing method employing the Baculovirus expression vector system (BEVS), a unique next-generation technology platform for manufacturing biopharmaceutical products. Daiichi Sankyo will conduct a basic research to determine the possibility to develop norovirus vaccine with a novel device.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze